Search
Xeruborbactam
go.drugbank.com/drugs/DB21512InvestigationalXeruborbactam is a small molecule drug. The usage of the INN stem '-bactam' in the name indicates that Xeruborbactam is a ẞ-lactamase inhibitor. … Xeruborbactam is under investigation in clinical trial NCT07104162 (A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment).
Gridegalutamide
go.drugbank.com/drugs/DB21593InvestigationalGridegalutamide is a small molecule drug. The usage of the INN stem '-lutamide' in the name indicates that Gridegalutamide is a non-steroid antiandrogen. … Gridegalutamide has a monoisotopic molecular weight of 818.32 Da.
Docirbrutinib
go.drugbank.com/drugs/DB21606InvestigationalDocirbrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Docirbrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor. … Docirbrutinib has a monoisotopic molecular weight of 578.24 Da.
Lomedeucitinib
go.drugbank.com/drugs/DB21649InvestigationalLomedeucitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor. … Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).
Bimokalner
go.drugbank.com/drugs/DB21717InvestigationalBimokalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Bimokalner is a opener of calcium-activated (maxi-K) K+-channel. … Bimokalner has a monoisotopic molecular weight of 355.1 Da.
Naftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum
International brands: A MeiiCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
Pelitinib
go.drugbank.com/drugs/DB05524InvestigationalPelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
Synonyms: (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamideCG7870
go.drugbank.com/drugs/DB04981InvestigationalCG7870 is an oncolytic virus therapy for prostate cancer. … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.